1 Epidermolysis Bullosa Therapeutics Market Overview 1.1 Product Overview and Scope of Epidermolysis Bullosa Therapeutics 1.2 Epidermolysis Bullosa Therapeutics Segment by Type 1.2.1 Global Epidermolysis Bullosa Therapeutics Market Value Comparison by Type (2023-2029) 1.2.2 EB-201 1.2.3 FCX-007 1.2.4 ICX-RHY 1.2.5 INM-750 1.2.6 Others 1.3 Epidermolysis Bullosa Therapeutics Segment by Application 1.3.1 Global Epidermolysis Bullosa Therapeutics Market Value by Application: (2023-2029) 1.3.2 Clinic 1.3.3 Hospital 1.3.4 Others 1.4 Global Epidermolysis Bullosa Therapeutics Market Size Estimates and Forecasts 1.4.1 Global Epidermolysis Bullosa Therapeutics Revenue 2018-2029 1.4.2 Global Epidermolysis Bullosa Therapeutics Sales 2018-2029 1.4.3 Global Epidermolysis Bullosa Therapeutics Market Average Price (2018-2029) 1.5 Assumptions and Limitations 2 Epidermolysis Bullosa Therapeutics Market Competition by Manufacturers 2.1 Global Epidermolysis Bullosa Therapeutics Sales Market Share by Manufacturers (2018-2023) 2.2 Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Manufacturers (2018-2023) 2.3 Global Epidermolysis Bullosa Therapeutics Average Price by Manufacturers (2018-2023) 2.4 Global Epidermolysis Bullosa Therapeutics Industry Ranking 2021 VS 2022 VS 2023 2.5 Global Key Manufacturers of Epidermolysis Bullosa Therapeutics, Manufacturing Sites & Headquarters 2.6 Global Key Manufacturers of Epidermolysis Bullosa Therapeutics, Product Type & Application 2.7 Epidermolysis Bullosa Therapeutics Market Competitive Situation and Trends 2.7.1 Epidermolysis Bullosa Therapeutics Market Concentration Rate 2.7.2 The Global Top 5 and Top 10 Largest Epidermolysis Bullosa Therapeutics Players Market Share by Revenue 2.7.3 Global Epidermolysis Bullosa Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.8 Manufacturers Mergers & Acquisitions, Expansion Plans 3 Epidermolysis Bullosa Therapeutics Retrospective Market Scenario by Region 3.1 Global Epidermolysis Bullosa Therapeutics Market Size by Region: 2018 Versus 2022 Versus 2029 3.2 Global Epidermolysis Bullosa Therapeutics Global Epidermolysis Bullosa Therapeutics Sales by Region: 2018-2029 3.2.1 Global Epidermolysis Bullosa Therapeutics Sales by Region: 2018-2023 3.2.2 Global Epidermolysis Bullosa Therapeutics Sales by Region: 2024-2029 3.3 Global Epidermolysis Bullosa Therapeutics Global Epidermolysis Bullosa Therapeutics Revenue by Region: 2018-2029 3.3.1 Global Epidermolysis Bullosa Therapeutics Revenue by Region: 2018-2023 3.3.2 Global Epidermolysis Bullosa Therapeutics Revenue by Region: 2024-2029 3.4 North America Epidermolysis Bullosa Therapeutics Market Facts & Figures by Country 3.4.1 North America Epidermolysis Bullosa Therapeutics Market Size by Country: 2018 VS 2022 VS 2029 3.4.2 North America Epidermolysis Bullosa Therapeutics Sales by Country (2018-2029) 3.4.3 North America Epidermolysis Bullosa Therapeutics Revenue by Country (2018-2029) 3.4.4 U.S. 3.4.5 Canada 3.5 Europe Epidermolysis Bullosa Therapeutics Market Facts & Figures by Country 3.5.1 Europe Epidermolysis Bullosa Therapeutics Market Size by Country: 2018 VS 2022 VS 2029 3.5.2 Europe Epidermolysis Bullosa Therapeutics Sales by Country (2018-2029) 3.5.3 Europe Epidermolysis Bullosa Therapeutics Revenue by Country (2018-2029) 3.5.4 Germany 3.5.5 France 3.5.6 U.K. 3.5.7 Italy 3.5.8 Russia 3.6 Asia Pacific Epidermolysis Bullosa Therapeutics Market Facts & Figures by Country 3.6.1 Asia Pacific Epidermolysis Bullosa Therapeutics Market Size by Country: 2018 VS 2022 VS 2029 3.6.2 Asia Pacific Epidermolysis Bullosa Therapeutics Sales by Country (2018-2029) 3.6.3 Asia Pacific Epidermolysis Bullosa Therapeutics Revenue by Country (2018-2029) 3.6.4 China 3.6.5 Japan 3.6.6 South Korea 3.6.7 India 3.6.8 Australia 3.6.9 Taiwan 3.6.10 Indonesia 3.6.11 Thailand 3.6.12 Malaysia 3.6.13 Philippines 3.7 Latin America Epidermolysis Bullosa Therapeutics Market Facts & Figures by Country 3.7.1 Latin America Epidermolysis Bullosa Therapeutics Market Size by Country: 2018 VS 2022 VS 2029 3.7.2 Latin America Epidermolysis Bullosa Therapeutics Sales by Country (2018-2029) 3.7.3 Latin America Epidermolysis Bullosa Therapeutics Revenue by Country (2018-2029) 3.7.4 Mexico 3.7.5 Brazil 3.7.6 Argentina 3.8 Middle East and Africa Epidermolysis Bullosa Therapeutics Market Facts & Figures by Country 3.8.1 Middle East and Africa Epidermolysis Bullosa Therapeutics Market Size by Country: 2018 VS 2022 VS 2029 3.8.2 Middle East and Africa Epidermolysis Bullosa Therapeutics Sales by Country (2018-2029) 3.8.3 Middle East and Africa Epidermolysis Bullosa Therapeutics Revenue by Country (2018-2029) 3.8.4 Turkey 3.8.5 Saudi Arabia 3.8.6 U.A.E 4 Segment by Type 4.1 Global Epidermolysis Bullosa Therapeutics Sales by Type (2018-2029) 4.1.1 Global Epidermolysis Bullosa Therapeutics Sales by Type (2018-2023) 4.1.2 Global Epidermolysis Bullosa Therapeutics Sales by Type (2024-2029) 4.1.3 Global Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2018-2029) 4.2 Global Epidermolysis Bullosa Therapeutics Revenue by Type (2018-2029) 4.2.1 Global Epidermolysis Bullosa Therapeutics Revenue by Type (2018-2023) 4.2.2 Global Epidermolysis Bullosa Therapeutics Revenue by Type (2024-2029) 4.2.3 Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Type (2018-2029) 4.3 Global Epidermolysis Bullosa Therapeutics Price by Type (2018-2029) 5 Segment by Application 5.1 Global Epidermolysis Bullosa Therapeutics Sales by Application (2018-2029) 5.1.1 Global Epidermolysis Bullosa Therapeutics Sales by Application (2018-2023) 5.1.2 Global Epidermolysis Bullosa Therapeutics Sales by Application (2024-2029) 5.1.3 Global Epidermolysis Bullosa Therapeutics Sales Market Share by Application (2018-2029) 5.2 Global Epidermolysis Bullosa Therapeutics Revenue by Application (2018-2029) 5.2.1 Global Epidermolysis Bullosa Therapeutics Revenue by Application (2018-2023) 5.2.2 Global Epidermolysis Bullosa Therapeutics Revenue by Application (2024-2029) 5.2.3 Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Application (2018-2029) 5.3 Global Epidermolysis Bullosa Therapeutics Price by Application (2018-2029) 6 Key Companies Profiled 6.1 Birken AG 6.1.1 Birken AG Corporation Information 6.1.2 Birken AG Description and Business Overview 6.1.3 Birken AG Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2018-2023) 6.1.4 Birken AG Epidermolysis Bullosa Therapeutics Product Portfolio 6.1.5 Birken AG Recent Developments/Updates 6.2 Fibrocell Science, Inc. 6.2.1 Fibrocell Science, Inc. Corporation Information 6.2.2 Fibrocell Science, Inc. Description and Business Overview 6.2.3 Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2018-2023) 6.2.4 Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Product Portfolio 6.2.5 Fibrocell Science, Inc. Recent Developments/Updates 6.3 GlaxoSmithKline Plc 6.3.1 GlaxoSmithKline Plc Corporation Information 6.3.2 GlaxoSmithKline Plc Description and Business Overview 6.3.3 GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2018-2023) 6.3.4 GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Product Portfolio 6.3.5 GlaxoSmithKline Plc Recent Developments/Updates 6.4 InMed Pharmaceuticals Inc. 6.4.1 InMed Pharmaceuticals Inc. Corporation Information 6.4.2 InMed Pharmaceuticals Inc. Description and Business Overview 6.4.3 InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2018-2023) 6.4.4 InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Product Portfolio 6.4.5 InMed Pharmaceuticals Inc. Recent Developments/Updates 6.5 Karus Therapeutics Limited 6.5.1 Karus Therapeutics Limited Corporation Information 6.5.2 Karus Therapeutics Limited Description and Business Overview 6.5.3 Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2018-2023) 6.5.4 Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Product Portfolio 6.5.5 Karus Therapeutics Limited Recent Developments/Updates 6.6 ProQR Therapeutics N.V. 6.6.1 ProQR Therapeutics N.V. Corporation Information 6.6.2 ProQR Therapeutics N.V. Description and Business Overview 6.6.3 ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2018-2023) 6.6.4 ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Product Portfolio 6.6.5 ProQR Therapeutics N.V. Recent Developments/Updates 6.7 RegeneRx Biopharmaceuticals, Inc. 6.6.1 RegeneRx Biopharmaceuticals, Inc. Corporation Information 6.6.2 RegeneRx Biopharmaceuticals, Inc. Description and Business Overview 6.6.3 RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2018-2023) 6.4.4 RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Product Portfolio 6.7.5 RegeneRx Biopharmaceuticals, Inc. Recent Developments/Updates 6.8 Scioderm, Inc. 6.8.1 Scioderm, Inc. Corporation Information 6.8.2 Scioderm, Inc. Description and Business Overview 6.8.3 Scioderm, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2018-2023) 6.8.4 Scioderm, Inc. Epidermolysis Bullosa Therapeutics Product Portfolio 6.8.5 Scioderm, Inc. Recent Developments/Updates 6.9 Stratatech Corporation 6.9.1 Stratatech Corporation Corporation Information 6.9.2 Stratatech Corporation Description and Business Overview 6.9.3 Stratatech Corporation Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2018-2023) 6.9.4 Stratatech Corporation Epidermolysis Bullosa Therapeutics Product Portfolio 6.9.5 Stratatech Corporation Recent Developments/Updates 6.10 TWi Pharmaceuticals, Inc. 6.10.1 TWi Pharmaceuticals, Inc. Corporation Information 6.10.2 TWi Pharmaceuticals, Inc. Description and Business Overview 6.10.3 TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2018-2023) 6.10.4 TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Product Portfolio 6.10.5 TWi Pharmaceuticals, Inc. Recent Developments/Updates 6.11 WAVE Life Sciences Ltd. 6.11.1 WAVE Life Sciences Ltd. Corporation Information 6.11.2 WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Description and Business Overview 6.11.3 WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Sales, Revenue and Gross Margin (2018-2023) 6.11.4 WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Product Portfolio 6.11.5 WAVE Life Sciences Ltd. Recent Developments/Updates 7 Industry Chain and Sales Channels Analysis 7.1 Epidermolysis Bullosa Therapeutics Industry Chain Analysis 7.2 Epidermolysis Bullosa Therapeutics Key Raw Materials 7.2.1 Key Raw Materials 7.2.2 Raw Materials Key Suppliers 7.3 Epidermolysis Bullosa Therapeutics Production Mode & Process 7.4 Epidermolysis Bullosa Therapeutics Sales and Marketing 7.4.1 Epidermolysis Bullosa Therapeutics Sales Channels 7.4.2 Epidermolysis Bullosa Therapeutics Distributors 7.5 Epidermolysis Bullosa Therapeutics Customers 8 Epidermolysis Bullosa Therapeutics Market Dynamics 8.1 Epidermolysis Bullosa Therapeutics Industry Trends 8.2 Epidermolysis Bullosa Therapeutics Market Drivers 8.3 Epidermolysis Bullosa Therapeutics Market Challenges 8.4 Epidermolysis Bullosa Therapeutics Market Restraints 9 Research Finding and Conclusion 10 Methodology and Data Source 10.1 Methodology/Research Approach 10.1.1 Research Programs/Design 10.1.2 Market Size Estimation 10.1.3 Market Breakdown and Data Triangulation 10.2 Data Source 10.2.1 Secondary Sources 10.2.2 Primary Sources 10.3 Author List 10.4 Disclaimer

List of Tables Table 1. Global Epidermolysis Bullosa Therapeutics Market Value Comparison by Type (2023-2029) & (US$ Million) Table 2. Global Epidermolysis Bullosa Therapeutics Market Value Comparison by Application (2023-2029) & (US$ Million) Table 3. Global Epidermolysis Bullosa Therapeutics Market Competitive Situation by Manufacturers in 2022 Table 4. Global Epidermolysis Bullosa Therapeutics Sales (K Pcs) of Key Manufacturers (2018-2023) Table 5. Global Epidermolysis Bullosa Therapeutics Sales Market Share by Manufacturers (2018-2023) Table 6. Global Epidermolysis Bullosa Therapeutics Revenue (US$ Million) by Manufacturers (2018-2023) Table 7. Global Epidermolysis Bullosa Therapeutics Revenue Share by Manufacturers (2018-2023) Table 8. Global Market Epidermolysis Bullosa Therapeutics Average Price (USD/Pcs) of Key Manufacturers (2018-2023) Table 9. Global Key Players of Epidermolysis Bullosa Therapeutics, Industry Ranking, 2021 VS 2022 VS 2023 Table 10. Global Key Manufacturers of Epidermolysis Bullosa Therapeutics, Manufacturing Sites & Headquarters Table 11. Global Key Manufacturers of Epidermolysis Bullosa Therapeutics, Product Type & Application Table 12. Global Key Manufacturers of Epidermolysis Bullosa Therapeutics, Date of Enter into This Industry Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 14. Global Epidermolysis Bullosa Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Epidermolysis Bullosa Therapeutics as of 2022) Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans Table 16. Global Epidermolysis Bullosa Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2029 Table 17. Global Epidermolysis Bullosa Therapeutics Sales by Region (2018-2023) & (K Pcs) Table 18. Global Epidermolysis Bullosa Therapeutics Sales Market Share by Region (2018-2023) Table 19. Global Epidermolysis Bullosa Therapeutics Sales by Region (2024-2029) & (K Pcs) Table 20. Global Epidermolysis Bullosa Therapeutics Sales Market Share by Region (2024-2029) Table 21. Global Epidermolysis Bullosa Therapeutics Revenue by Region (2018-2023) & (US$ Million) Table 22. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Region (2018-2023) Table 23. Global Epidermolysis Bullosa Therapeutics Revenue by Region (2024-2029) & (US$ Million) Table 24. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Region (2024-2029) Table 25. North America Epidermolysis Bullosa Therapeutics Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million) Table 26. North America Epidermolysis Bullosa Therapeutics Sales by Country (2018-2023) & (K Pcs) Table 27. North America Epidermolysis Bullosa Therapeutics Sales by Country (2024-2029) & (K Pcs) Table 28. North America Epidermolysis Bullosa Therapeutics Revenue by Country (2018-2023) & (US$ Million) Table 29. North America Epidermolysis Bullosa Therapeutics Revenue by Country (2024-2029) & (US$ Million) Table 30. Europe Epidermolysis Bullosa Therapeutics Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million) Table 31. Europe Epidermolysis Bullosa Therapeutics Sales by Country (2018-2023) & (K Pcs) Table 32. Europe Epidermolysis Bullosa Therapeutics Sales by Country (2024-2029) & (K Pcs) Table 33. Europe Epidermolysis Bullosa Therapeutics Revenue by Country (2018-2023) & (US$ Million) Table 34. Europe Epidermolysis Bullosa Therapeutics Revenue by Country (2024-2029) & (US$ Million) Table 35. Asia Pacific Epidermolysis Bullosa Therapeutics Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million) Table 36. Asia Pacific Epidermolysis Bullosa Therapeutics Sales by Region (2018-2023) & (K Pcs) Table 37. Asia Pacific Epidermolysis Bullosa Therapeutics Sales by Region (2024-2029) & (K Pcs) Table 38. Asia Pacific Epidermolysis Bullosa Therapeutics Revenue by Region (2018-2023) & (US$ Million) Table 39. Asia Pacific Epidermolysis Bullosa Therapeutics Revenue by Region (2024-2029) & (US$ Million) Table 40. Latin America Epidermolysis Bullosa Therapeutics Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million) Table 41. Latin America Epidermolysis Bullosa Therapeutics Sales by Country (2018-2023) & (K Pcs) Table 42. Latin America Epidermolysis Bullosa Therapeutics Sales by Country (2024-2029) & (K Pcs) Table 43. Latin America Epidermolysis Bullosa Therapeutics Revenue by Country (2018-2023) & (US$ Million) Table 44. Latin America Epidermolysis Bullosa Therapeutics Revenue by Country (2024-2029) & (US$ Million) Table 45. Middle East & Africa Epidermolysis Bullosa Therapeutics Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million) Table 46. Middle East & Africa Epidermolysis Bullosa Therapeutics Sales by Country (2018-2023) & (K Pcs) Table 47. Middle East & Africa Epidermolysis Bullosa Therapeutics Sales by Country (2024-2029) & (K Pcs) Table 48. Middle East & Africa Epidermolysis Bullosa Therapeutics Revenue by Country (2018-2023) & (US$ Million) Table 49. Middle East & Africa Epidermolysis Bullosa Therapeutics Revenue by Country (2024-2029) & (US$ Million) Table 50. Global Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Type (2018-2023) Table 51. Global Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Type (2024-2029) Table 52. Global Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2018-2023) Table 53. Global Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2024-2029) Table 54. Global Epidermolysis Bullosa Therapeutics Revenue (US$ Million) by Type (2018-2023) Table 55. Global Epidermolysis Bullosa Therapeutics Revenue (US$ Million) by Type (2024-2029) Table 56. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Type (2018-2023) Table 57. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Type (2024-2029) Table 58. Global Epidermolysis Bullosa Therapeutics Price (USD/Pcs) by Type (2018-2023) Table 59. Global Epidermolysis Bullosa Therapeutics Price (USD/Pcs) by Type (2024-2029) Table 60. Global Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Application (2018-2023) Table 61. Global Epidermolysis Bullosa Therapeutics Sales (K Pcs) by Application (2024-2029) Table 62. Global Epidermolysis Bullosa Therapeutics Sales Market Share by Application (2018-2023) Table 63. Global Epidermolysis Bullosa Therapeutics Sales Market Share by Application (2024-2029) Table 64. Global Epidermolysis Bullosa Therapeutics Revenue (US$ Million) by Application (2018-2023) Table 65. Global Epidermolysis Bullosa Therapeutics Revenue (US$ Million) by Application (2024-2029) Table 66. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Application (2018-2023) Table 67. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Application (2024-2029) Table 68. Global Epidermolysis Bullosa Therapeutics Price (USD/Pcs) by Application (2018-2023) Table 69. Global Epidermolysis Bullosa Therapeutics Price (USD/Pcs) by Application (2024-2029) Table 70. Birken AG Corporation Information Table 71. Birken AG Description and Business Overview Table 72. Birken AG Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 73. Birken AG Epidermolysis Bullosa Therapeutics Product Table 74. Birken AG Recent Developments/Updates Table 75. Fibrocell Science, Inc. Corporation Information Table 76. Fibrocell Science, Inc. Description and Business Overview Table 77. Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 78. Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Product Table 79. Fibrocell Science, Inc. Recent Developments/Updates Table 80. GlaxoSmithKline Plc Corporation Information Table 81. GlaxoSmithKline Plc Description and Business Overview Table 82. GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 83. GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Product Table 84. GlaxoSmithKline Plc Recent Developments/Updates Table 85. InMed Pharmaceuticals Inc. Corporation Information Table 86. InMed Pharmaceuticals Inc. Description and Business Overview Table 87. InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 88. InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Product Table 89. InMed Pharmaceuticals Inc. Recent Developments/Updates Table 90. Karus Therapeutics Limited Corporation Information Table 91. Karus Therapeutics Limited Description and Business Overview Table 92. Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 93. Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Product Table 94. Karus Therapeutics Limited Recent Developments/Updates Table 95. ProQR Therapeutics N.V. Corporation Information Table 96. ProQR Therapeutics N.V. Description and Business Overview Table 97. ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 98. ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Product Table 99. ProQR Therapeutics N.V. Recent Developments/Updates Table 100. RegeneRx Biopharmaceuticals, Inc. Corporation Information Table 101. RegeneRx Biopharmaceuticals, Inc. Description and Business Overview Table 102. RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 103. RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Product Table 104. RegeneRx Biopharmaceuticals, Inc. Recent Developments/Updates Table 105. Scioderm, Inc. Corporation Information Table 106. Scioderm, Inc. Description and Business Overview Table 107. Scioderm, Inc. Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 108. Scioderm, Inc. Epidermolysis Bullosa Therapeutics Product Table 109. Scioderm, Inc. Recent Developments/Updates Table 110. Stratatech Corporation Corporation Information Table 111. Stratatech Corporation Description and Business Overview Table 112. Stratatech Corporation Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 113. Stratatech Corporation Epidermolysis Bullosa Therapeutics Product Table 114. Stratatech Corporation Recent Developments/Updates Table 115. TWi Pharmaceuticals, Inc. Corporation Information Table 116. TWi Pharmaceuticals, Inc. Description and Business Overview Table 117. TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 118. TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Product Table 119. TWi Pharmaceuticals, Inc. Recent Developments/Updates Table 120. WAVE Life Sciences Ltd. Corporation Information Table 121. WAVE Life Sciences Ltd. Description and Business Overview Table 122. WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2023) Table 123. WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Product Table 124. WAVE Life Sciences Ltd. Recent Developments/Updates Table 125. Key Raw Materials Lists Table 126. Raw Materials Key Suppliers Lists Table 127. Epidermolysis Bullosa Therapeutics Distributors List Table 128. Epidermolysis Bullosa Therapeutics Customers List Table 129. Epidermolysis Bullosa Therapeutics Market Trends Table 130. Epidermolysis Bullosa Therapeutics Market Drivers Table 131. Epidermolysis Bullosa Therapeutics Market Challenges Table 132. Epidermolysis Bullosa Therapeutics Market Restraints Table 133. Research Programs/Design for This Report Table 134. Key Data Information from Secondary Sources Table 135. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of Epidermolysis Bullosa Therapeutics Figure 2. Global Epidermolysis Bullosa Therapeutics Market Value Comparison by Type (2023-2029) & (US$ Million) Figure 3. Global Epidermolysis Bullosa Therapeutics Market Share by Type in 2022 & 2029 Figure 4. EB-201 Product Picture Figure 5. FCX-007 Product Picture Figure 6. ICX-RHY Product Picture Figure 7. INM-750 Product Picture Figure 8. Others Product Picture Figure 9. Global Epidermolysis Bullosa Therapeutics Market Value Comparison by Application (2023-2029) & (US$ Million) Figure 10. Global Epidermolysis Bullosa Therapeutics Market Share by Application in 2022 & 2029 Figure 11. Clinic Figure 12. Hospital Figure 13. Others Figure 14. Global Epidermolysis Bullosa Therapeutics Revenue, (US$ Million), 2018 VS 2022 VS 2029 Figure 15. Global Epidermolysis Bullosa Therapeutics Market Size (2018-2029) & (US$ Million) Figure 16. Global Epidermolysis Bullosa Therapeutics Sales (2018-2029) & (K Pcs) Figure 17. Global Epidermolysis Bullosa Therapeutics Average Price (USD/Pcs) & (2018-2029) Figure 18. Epidermolysis Bullosa Therapeutics Report Years Considered Figure 19. Epidermolysis Bullosa Therapeutics Sales Share by Manufacturers in 2022 Figure 20. Global Epidermolysis Bullosa Therapeutics Revenue Share by Manufacturers in 2022 Figure 21. The Global 5 and 10 Largest Epidermolysis Bullosa Therapeutics Players: Market Share by Revenue in 2022 Figure 22. Epidermolysis Bullosa Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022 Figure 23. Global Epidermolysis Bullosa Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2029 Figure 24. North America Epidermolysis Bullosa Therapeutics Sales Market Share by Country (2018-2029) Figure 25. North America Epidermolysis Bullosa Therapeutics Revenue Market Share by Country (2018-2029) Figure 26. U.S. Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 27. Canada Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 28. Europe Epidermolysis Bullosa Therapeutics Sales Market Share by Country (2018-2029) Figure 29. Europe Epidermolysis Bullosa Therapeutics Revenue Market Share by Country (2018-2029) Figure 30. Germany Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 31. France Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 32. U.K. Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 33. Italy Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 34. Russia Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 35. Asia Pacific Epidermolysis Bullosa Therapeutics Sales Market Share by Region (2018-2029) Figure 36. Asia Pacific Epidermolysis Bullosa Therapeutics Revenue Market Share by Region (2018-2029) Figure 37. China Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 38. Japan Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 39. South Korea Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 40. India Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 41. Australia Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 42. Taiwan Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 43. Indonesia Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 44. Thailand Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 45. Malaysia Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 46. Philippines Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 47. Latin America Epidermolysis Bullosa Therapeutics Sales Market Share by Country (2018-2029) Figure 48. Latin America Epidermolysis Bullosa Therapeutics Revenue Market Share by Country (2018-2029) Figure 49. Mexico Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 50. Brazil Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 51. Argentina Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 52. Middle East & Africa Epidermolysis Bullosa Therapeutics Sales Market Share by Country (2018-2029) Figure 53. Middle East & Africa Epidermolysis Bullosa Therapeutics Revenue Market Share by Country (2018-2029) Figure 54. Turkey Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 55. Saudi Arabia Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 56. U.A.E Epidermolysis Bullosa Therapeutics Revenue Growth Rate (2018-2029) & (US$ Million) Figure 57. Global Sales Market Share of Epidermolysis Bullosa Therapeutics by Type (2018-2029) Figure 58. Global Revenue Market Share of Epidermolysis Bullosa Therapeutics by Type (2018-2029) Figure 59. Global Epidermolysis Bullosa Therapeutics Price (USD/Pcs) by Type (2018-2029) Figure 60. Global Sales Market Share of Epidermolysis Bullosa Therapeutics by Application (2018-2029) Figure 61. Global Revenue Market Share of Epidermolysis Bullosa Therapeutics by Application (2018-2029) Figure 62. Global Epidermolysis Bullosa Therapeutics Price (USD/Pcs) by Application (2018-2029) Figure 63. Epidermolysis Bullosa Therapeutics Value Chain Figure 64. Epidermolysis Bullosa Therapeutics Production Process Figure 65. Channels of Distribution (Direct Vs Distribution) Figure 66. Distributors Profiles Figure 67. Bottom-up and Top-down Approaches for This Report Figure 68. Data Triangulation Figure 69. Key Executives Interviewed

Birken AG Fibrocell Science, Inc. GlaxoSmithKline Plc InMed Pharmaceuticals Inc. Karus Therapeutics Limited ProQR Therapeutics N.V. RegeneRx Biopharmaceuticals, Inc. Scioderm, Inc. Stratatech Corporation TWi Pharmaceuticals, Inc. WAVE Life Sciences Ltd.